{"id":2111,"date":"2025-09-17T15:50:09","date_gmt":"2025-09-17T15:50:09","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=2111"},"modified":"2026-02-22T00:49:37","modified_gmt":"2026-02-22T00:49:37","slug":"six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/","title":{"rendered":"Six at Sixty. \u2018No gain, no pain\u2019: medical genetics taking Nav1.7 from target to pharmacy (Contributed by Pu Xia)"},"content":{"rendered":"

Chronic pain affects millions, but opioid painkillers bring addiction, tolerance and fatal breathing risks. The voltage-gated sodium channel Nav1.7, encoded by SCN9A<\/em>, is key in pain signaling. 2004 research linked its gain-of-function mutations to primary erythromelalgia, and 2006 work connected loss-of-function mutations to congenital insensitivity to pain, making it a therapeutic target. Though Nav1.7 inhibitor development faced challenges, 2025\u2019s FDA approval of Nav1.8 inhibitor suzetrigine, a milestone in non-opioid analgesia, showing genetics’ role in advancing medicine. (https:\/\/jmg.bmj.com\/content\/early\/2025\/09\/11\/jmg-2025-111174<\/a> )<\/p>\n

\"\"<\/a><\/p>\n

Group Photo of the Genetic Skin Disease Center, Jiangsu Key Laboratory of Molecular Biology for Skin Diseases and STIs<\/p>\n","protected":false},"excerpt":{"rendered":"

Chronic pain affects millions, but opioid painkillers bring addiction, tolerance and fatal breathing risks. The voltage-gated sodium channel Nav1.7, encoded by SCN9A, is key in pain signaling. 2004 research linked its gain-of-function mutations to primary erythromelalgia, and 2006 work connected loss-of-function mutations to congenital insensitivity to pain, making it a therapeutic target. Though Nav1.7 inhibitor […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2111","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nSix at Sixty. \u2018No gain, no pain\u2019: medical genetics taking Nav1.7 from target to pharmacy (Contributed by Pu Xia) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Six at Sixty. \u2018No gain, no pain\u2019: medical genetics taking Nav1.7 from target to pharmacy (Contributed by Pu Xia) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Chronic pain affects millions, but opioid painkillers bring addiction, tolerance and fatal breathing risks. The voltage-gated sodium channel Nav1.7, encoded by SCN9A, is key in pain signaling. 2004 research linked its gain-of-function mutations to primary erythromelalgia, and 2006 work connected loss-of-function mutations to congenital insensitivity to pain, making it a therapeutic target. Though Nav1.7 inhibitor [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-17T15:50:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-22T00:49:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jmg\/files\/2025\/09\/group-photo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2237\" \/>\n\t<meta property=\"og:image:height\" content=\"1132\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"Six at Sixty. \u2018No gain, no pain\u2019: medical genetics taking Nav1.7 from target to pharmacy (Contributed by Pu Xia)\",\"datePublished\":\"2025-09-17T15:50:09+00:00\",\"dateModified\":\"2026-02-22T00:49:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/\"},\"wordCount\":121,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2025\\\/09\\\/group-photo-300x152.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/\",\"name\":\"Six at Sixty. \u2018No gain, no pain\u2019: medical genetics taking Nav1.7 from target to pharmacy (Contributed by Pu Xia) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2025\\\/09\\\/group-photo-300x152.jpg\",\"datePublished\":\"2025-09-17T15:50:09+00:00\",\"dateModified\":\"2026-02-22T00:49:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2025\\\/09\\\/group-photo.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2025\\\/09\\\/group-photo.jpg\",\"width\":2237,\"height\":1132},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2025\\\/09\\\/17\\\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Six at Sixty. \u2018No gain, no pain\u2019: medical genetics taking Nav1.7 from target to pharmacy (Contributed by Pu Xia)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Six at Sixty. \u2018No gain, no pain\u2019: medical genetics taking Nav1.7 from target to pharmacy (Contributed by Pu Xia) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/","og_locale":"en_US","og_type":"article","og_title":"Six at Sixty. \u2018No gain, no pain\u2019: medical genetics taking Nav1.7 from target to pharmacy (Contributed by Pu Xia) - JMG Contact blog","og_description":"Chronic pain affects millions, but opioid painkillers bring addiction, tolerance and fatal breathing risks. The voltage-gated sodium channel Nav1.7, encoded by SCN9A, is key in pain signaling. 2004 research linked its gain-of-function mutations to primary erythromelalgia, and 2006 work connected loss-of-function mutations to congenital insensitivity to pain, making it a therapeutic target. Though Nav1.7 inhibitor [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/","og_site_name":"JMG Contact blog","article_published_time":"2025-09-17T15:50:09+00:00","article_modified_time":"2026-02-22T00:49:37+00:00","og_image":[{"width":2237,"height":1132,"url":"https:\/\/blogs.bmj.com\/jmg\/files\/2025\/09\/group-photo.jpg","type":"image\/jpeg"}],"author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"Six at Sixty. \u2018No gain, no pain\u2019: medical genetics taking Nav1.7 from target to pharmacy (Contributed by Pu Xia)","datePublished":"2025-09-17T15:50:09+00:00","dateModified":"2026-02-22T00:49:37+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/"},"wordCount":121,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2025\/09\/group-photo-300x152.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/","url":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/","name":"Six at Sixty. \u2018No gain, no pain\u2019: medical genetics taking Nav1.7 from target to pharmacy (Contributed by Pu Xia) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2025\/09\/group-photo-300x152.jpg","datePublished":"2025-09-17T15:50:09+00:00","dateModified":"2026-02-22T00:49:37+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2025\/09\/group-photo.jpg","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2025\/09\/group-photo.jpg","width":2237,"height":1132},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2025\/09\/17\/six-at-sixty-no-gain-no-pain-medical-genetics-taking-nav1-7-from-target-to-pharmacy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"Six at Sixty. \u2018No gain, no pain\u2019: medical genetics taking Nav1.7 from target to pharmacy (Contributed by Pu Xia)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/2111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=2111"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/2111\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=2111"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=2111"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=2111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}